U.S. markets close in 5 hours 38 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
228.08+1.38 (+0.61%)
As of 10:22AM EST. Market open.
Sign in to post a message.
  • S
    (ETTX) trading at CASH and has 2x BIG Phase 3 Drugs with imminent readout =MEGA OPP

    ETTX =Price $1.75 /MCap $63 Million /Cash $62 Million /2x MEGA Phase 3 Drugs with first readout expected next Quarter / Astrazeneca Spinoff =1000%++ UPSIDE here ...GLTA

  • V
    Any investors in CRSP besides VRTX?
  • A
  • j
    jay m
    Market is wildly missing the opportunity here. VRTX has one of the best balance sheets and growth profiles in the entire market. Absolute blowout quarter following a massive over-reaction to news about a non-contributing pre-commercial R&D pipeline candidate. The pipeline remains stacked and the CF franchise is protected and dominant for years to come.
  • W
    this behemoth has basically $500M in debt, $6B in hoard cash, and huge qtrly growth prospects. my bet is they will hit $275 by 3/2021; leiden can run my company any day......
  • R
    Webcast 12/9. Big move up coming.
  • A
    Lots of whining on the Arrowhead board after a HUGE earnings miss! Getting haammered pre-market again. Now it's their turn to suffer through the mass of downgrades coming their way! There is just no one who can compete with the leader - VRTX!!!
  • R
    Rojo Span

    A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

    The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
    ClinicalTrials.gov Identifier: NCT04269031
    Recruitment Status : Recruiting
    First Posted : February 13, 2020
    Last Update Posted : September 24, 2020
    See Contacts and Locations
    Information provided by (Responsible Party):

    • Study Details
    • Tabular View
    • No Results Posted
    • Disclaimer
    • How to Read a Study Record
    Study Description

    Go to  
    Brief Summary:
    This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.

    Condition or disease
    Healthy Volunteers
    Drug: AZD2373 subcutaneous injection
    Drug: Placebo
    Phase 1

    Detailed Description:
    This study will be conducted as a single-centre, randomised, placebo-controlled, single-blind study to assess the effect of AZD2373 following ascending dose sequential group design administrations to healthy male subjects of African ancestry. The study will include 6 single dose cohorts with the option to include 2 additional cohorts based on emerging data from preceding cohorts in the study.
    Approximately 48 male subjects aged 18 to 50 years at the time of informed consent (inclusive) will be randomized with the aim to have 8 subjects participate in each cohort. Within each cohort, 6 subjects will receive AZD2373 and 2 subjects will receive placebo.
    Sentinel dosing will be applied for each cohort and will be divided into 2 groups:
    • Group 1 (sentinel group): 1 active, 1 placebo;
    • Group 2 (the rest of the cohort): 5 active, 1 placebo. The safety data of up to 72 hours post-dose in Group 1 will be reviewed by the Principal Investigator (PI) before the subjects in Group 2 are dosed.
    The study will comprise:
    • A Screening Period of maximum 28 days;
    • A Treatment Period during which subjects will be resident at the Clinical Unit from the day before investigational medicinal product (IMP) administration (Day 1) until at least 72 hours after IMP administration; discharged from the Clinical Unit on Day 4;
    • Follow-up Visits on 1, 1.5, 2, 3, 4, 5, 6, and 8 weeks (Visits 3 to 10); and
    • A Final Follow up Visit 10 weeks after the last IMP dose.
    The expected duration for any subject participating in the study is approximately 10 weeks (excluding an up to 28-day Screening Period).
    Study Design
    Home - ClinicalTrials.gov
  • a
    Gladpick your request has been adopted by the board! 500 million buyback!
  • C
    Vertex has stellar track records!!!
    7 consecutive quarters earnings beat! Trading at PE ration 21!
    Gross Profit 88%
    Net profit 45%
    Return on equity 40%
    Tons of cash on hand!
    Low debt!
    Recent EU approval for CF drugs!
    More sales revenue to come from countries worldwide!
    Pipe line include diabetes, collaboration Moderna, promising trial result with Crispr coming 2021!
    Will be foolish not to take advantage of the stock on sale now!!!
  • I
    Just initiated a position in VRTX! Appears to be a great opportunity at this level!
  • R
    Rojo Span
    If history is the guide and once i think about VRTX backup sister molecules, once initial molecule failed, second molecule failed as well. Long list from aurora kinase inhibitors, inflammatory kinases to hep c molecules to pain NaV 1.8 and 1.7 inhibitors. So if someone is positive for VX 863, think twice and think where VRTX price will be if bad news comes out? Remember CEO said “ idiosyncratic” after monkey 🐒 around VX814 for 3 years. MRNA is a bigger company than VRTX today or I guess VRTX is a smaller company than MRNA.
  • S
    Initiates Coverage On Sanford Bernstein Outperform USD 275
  • s
    simply wall street values this at $355, whats with the very low current price?
  • T
    Just bought some shares right above 210. Thanks for the gift!
  • G
    Sellers and shorts seem to be in charge. Maybe VRTX should consider buying its own share for as cheap as they are with its cash hoard and the $2B credit facility rather than doing nothing as it is doing. If it were planning to buy another company to expand its pipeline, Reshma needs to get off her #$%$ and move. She simply needs to do something to stop the bleeding!
  • T
    form 3 q earnings call: We have a strong leadership position in cystic fibrosis, and we believe this will last a very long time into at least the late 2030s as a base case when considering the high bar set by the significant benefit of TRIKAFTA to patients and the patent coverage for this regimen
  • J
    I got lucky and recently bought at 202$ and change. Big gap to fill on the upside above 230$. Share buyback should Kickstart that move!
  • T
    "In addition to VX-814, Vertex is also testing VX-864 in a midstage study in patients with AATD. Data from that study is expected in the first half of 2021.

    Vertex is also researching additional back-up molecules for AATD. The biotech thinks it'll be able to advance at least one of them into development in 2021.
    Stopping development of VX-814 is certainly disappointing, but October's decline seems like an overreaction, given how early in development the drug was"